Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?

详细信息    查看全文

• 作者：Qinghua Hu (1)
  Lingjin Huang (1)
  Xuyuan Kuang (2)
  Heng Zhang (1)
  Guoqiang Ling (1)
  Xuliang Chen (1)
  Kejiang Li (2)
  Zhenghao Deng (3)
  Jianhua Zhou (3)
  
• 关键词：Insulin ; like growth factor binding protein ; Non ; small cell lung cancer ; Metastasis ; Microvesicles ; Intratumor heterogeneity
• 刊名：Clinical & Experimental Metastasis
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：31
• 期：5
• 页码：535-541
• 全文大小：
• 参考文献：1. Gao J, Chang YS, Jallal B, Viner J (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 73:3-2 CrossRef
  2. Holmes KM, Annala M, Chua CY et al (2012) Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci USA 109:3475-480 CrossRef
  3. Probst-Hensch NM, Steiner JH, Schraml P et al (2010) IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 16:1025-032 CrossRef
  4. Lancaster JM, Sayer RA, Blanchette C et al (2006) High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer 16:1529-535 CrossRef
  5. Uzoh CC, Holly JM, Biernacka KM et al (2011) Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104:1587-593 CrossRef
  6. Ladd JJ, Busald T, Johnson MM et al (2012) Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila) 5:655-64 CrossRef
  7. Lee DY, Kim SJ, Lee YC (1999) Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14:401-04
  8. Yu CJ, Wang CL, Wang CI et al (2011) Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J Proteome Res 10:4671-682 CrossRef
  9. Matuschek C, Rudoy M, Peiper M et al (2011) Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res 16:451-56 CrossRef
  10. Reeve JG, Morgan J, Schwander J, Bleehen NM (1993) Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53:4680-685
  11. Yazawa T, Sato H, Shimoyamada H et al (2009) Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 175:976-87 CrossRef
  12. Yazawa T, Sato H, Shimoyamada H et al (2007) Growth regulation via insulin-like growth factor binding protein-4 and -2 in lung epithelial cells and cancers. J Thorac oncol 2:S551–S556 CrossRef
  13. Kay F, Saskia G, Holger E, Walter J (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641-647 CrossRef
  14. Haqqani AS, Delaney CE, Tremblay TL et al (2013) Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS 10:4-0 CrossRef
  15. Herbert Yu, Rohan Thomas (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-489 CrossRef
  16. Sato H, Yazawa T, Suzuki T et al (2006) Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 169:1550-566 CrossRef
  17. Migita T, Narita T, Asaka R et al (2010) Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol 176:1756-766 CrossRef
  18. Azar WJ, Azar SH, Higgins S et al (2011) IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152:3332-342 CrossRef
  19. Azar WJ, Zivkovic S, Werther GA, Russo VC (2013) IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene 25:1-1
  20. Russo VC, Schütt BS, Andaloro E et al (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445-455 CrossRef
  21. Png KJ, Halberg N, Yoshida M, Tavazoie SF (2011) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481:190-94 CrossRef
  22. Guo C, Lu H, Gao W et al (2013) Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS ONE 8:e74973–e74980 CrossRef
  23. Martins VR, Dias MS, Hainaut P (2013) Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 25:66-5 CrossRef
  24. Swanton C (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res 72:4875-882 CrossRef
  
• 作者单位：Qinghua Hu (1)
  Lingjin Huang (1)
  Xuyuan Kuang (2)
  Heng Zhang (1)
  Guoqiang Ling (1)
  Xuliang Chen (1)
  Kejiang Li (2)
  Zhenghao Deng (3)
  Jianhua Zhou (3)
  
  1. Department of Cardiothoracic Surgery, Xiangya Hospital, Central-South University, Changsha, 410078, Hunan, China
  2. Xiangya Medical School, Central-South University, Changsha, 410008, Hunan, China
  3. Department of Pathology, Xiangya Hospital, Central-South University, Changsha, 410078, Hunan, China
  
• ISSN：1573-7276

文摘

Insulin-like growth factor binding protein 2 (IGFBP2) is involved in the progression of many epithelial cancers. However, its role in non-small cell lung cancer (NSCLC), another type of epithelial cancer, remains unclear. We detected IGFBP2 expression using immunohistochemistry in surgically resected tumors from 110 NSCLC patients, 37 of which had metastases. The positive rate of IGFBP2 expression was compared between the metastatic and the non-metastatic group, and correlations of IGFBP2 expression with metastasis and overall survival were analyzed. We also investigated the expression of IGFBP2 in microvesicles (MVs) collected from primary lung cancer cell cultures, and in different locations of newly resected NSCLC tumors, using immunoblotting. The overall positive rate of IGFBP2 expression in lung cancer was 51.8?% and it was significantly higher in the metastatic group than in the non-metastatic group (70.3 and 42.5?% respectively, p?<?0.01). And the higher the lymph node stage, the higher the positive rate. Cytoplasmic expression was predominant in the majority of the tumors. Based on multivariate regression analysis, IGFBP2 was correlated with metastasis and poor overall survival (Hazard ratio: 3.56 and 3.23 respectively). IGFBP2 was detectable in the MVs collected from IGFBP2 positive cell lines, and its expression was most abundant in the marginal region of the newly resected tumors. IGFBP2 is associated with metastasis and poor survival of lung cancer. Its presence in MVs and high abundance in the marginal region of tumors suggest that its association with metastasis may be related to tumor microenviroment remodeling in NSCLC.